Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.39
(-12.36%)
AUD 0.39
(-12.36%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 10.87 Million AUD | 7.94% |
| 2023 | 10.07 Million AUD | 86.72% |
| 2022 | 5.39 Million AUD | -37.25% |
| 2021 | 8.59 Million AUD | 54.82% |
| 2020 | 5.55 Million AUD | 53.41% |
| 2019 | 3.62 Million AUD | -34.1% |
| 2018 | 5.49 Million AUD | 90.18% |
| 2017 | 2.88 Million AUD | 78.06% |
| 2016 | 1.62 Million AUD | -35.92% |
| 2015 | 2.53 Million AUD | -51.62% |
| 2014 | 5.23 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 10.87 Million AUD | 0.0% |
| 2024 Q2 | 6.94 Million AUD | 0.0% |
| 2024 FY | 10.87 Million AUD | 7.94% |
| 2023 Q4 | 10.07 Million AUD | 0.0% |
| 2023 FY | 10.07 Million AUD | 86.72% |
| 2023 Q3 | 10.07 Million AUD | 12.52% |
| 2023 Q1 | 8.95 Million AUD | 65.95% |
| 2023 Q2 | 8.95 Million AUD | 0.0% |
| 2022 Q2 | 5.98 Million AUD | 0.0% |
| 2022 Q4 | 5.39 Million AUD | 0.0% |
| 2022 FY | 5.39 Million AUD | -37.25% |
| 2022 Q3 | 5.39 Million AUD | -9.9% |
| 2021 Q4 | 8.59 Million AUD | 0.0% |
| 2021 Q3 | 8.59 Million AUD | -8.45% |
| 2021 FY | 8.59 Million AUD | 54.82% |
| 2021 Q1 | 9.39 Million AUD | 69.11% |
| 2021 Q2 | 9.39 Million AUD | 0.0% |
| 2020 Q4 | 5.55 Million AUD | 0.0% |
| 2020 FY | 5.55 Million AUD | 53.41% |
| 2020 Q3 | 5.55 Million AUD | -4.34% |
| 2020 Q2 | 5.8 Million AUD | 0.0% |
| 2019 Q3 | 3.62 Million AUD | -8.41% |
| 2019 Q4 | 3.62 Million AUD | 0.0% |
| 2019 FY | 3.62 Million AUD | -34.1% |
| 2019 Q1 | 3.95 Million AUD | -28.05% |
| 2019 Q2 | 3.95 Million AUD | 0.0% |
| 2018 Q1 | 1.81 Million AUD | -37.18% |
| 2018 Q4 | 5.49 Million AUD | 0.0% |
| 2018 FY | 5.49 Million AUD | 90.18% |
| 2018 Q2 | 1.81 Million AUD | 0.0% |
| 2018 Q3 | 5.49 Million AUD | 202.72% |
| 2017 Q1 | 2.61 Million AUD | 60.9% |
| 2017 FY | 2.88 Million AUD | 78.06% |
| 2017 Q4 | 2.88 Million AUD | 0.0% |
| 2017 Q2 | 2.61 Million AUD | 0.0% |
| 2017 Q3 | 2.88 Million AUD | 10.67% |
| 2016 Q3 | 1.62 Million AUD | -3.09% |
| 2016 Q1 | 1.67 Million AUD | -33.88% |
| 2016 FY | 1.62 Million AUD | -35.92% |
| 2016 Q4 | 1.62 Million AUD | 0.0% |
| 2016 Q2 | 1.67 Million AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | 2.53 Million AUD | 0.0% |
| 2015 FY | 2.53 Million AUD | -51.62% |
| 2015 Q3 | 2.53 Million AUD | 0.0% |
| 2014 FY | 5.23 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AdAlta Limited | 5.57 Million AUD | -95.139% |
| Acrux Limited | 8.96 Million AUD | -21.333% |
| Actinogen Medical Limited | 21.31 Million AUD | 48.972% |
| AnteoTech Limited | 9.38 Million AUD | -15.925% |
| Argenica Therapeutics Limited | 16.37 Million AUD | 33.597% |
| Arovella Therapeutics Limited | 13.28 Million AUD | 18.138% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -550.65% |
| Alterity Therapeutics Limited | 19.22 Million AUD | 43.429% |
| Amplia Therapeutics Limited | 14.84 Million AUD | 26.743% |
| Avecho Biotechnology Limited | 7.31 Million AUD | -48.581% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -244.194% |
| Biome Australia Limited | 8.27 Million AUD | -31.393% |
| Biotron Limited | 493.47 Thousand AUD | -2103.777% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | 90.33% |
| BTC Health Limited | 5.14 Million AUD | -111.216% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | 28.796% |
| CSL Limited | 56.93 Billion AUD | 99.981% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 92.967% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 95.295% |
| Cynata Therapeutics Limited | 8.38 Million AUD | -29.646% |
| Dimerix Limited | 32.07 Million AUD | 66.098% |
| EZZ Life Science Holdings Limited | 25.55 Million AUD | 57.439% |
| Hexima Limited | 2.26 Million AUD | -379.29% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -324.068% |
| Immuron Limited | 15.54 Million AUD | 30.063% |
| Immutep Limited | 147.44 Million AUD | 92.624% |
| Imugene Limited | 151.39 Million AUD | 92.817% |
| Invex Therapeutics Ltd | 6.12 Million AUD | -77.696% |
| Memphasys Limited | 12.43 Million AUD | 12.51% |
| Nanollose Limited | 241.95 Thousand AUD | -4394.758% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | 95.614% |
| Noxopharm Limited | 6.78 Million AUD | -60.311% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -100.062% |
| Nyrada Inc. | 5.9 Million AUD | -84.097% |
| Orthocell Limited | 26.61 Million AUD | 59.139% |
| PharmAust Limited | 11.12 Million AUD | 2.245% |
| Patrys Limited | 4.16 Million AUD | -161.322% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 60.296% |
| Prescient Therapeutics Limited | 20.39 Million AUD | 46.672% |
| PYC Therapeutics Limited | 91.23 Million AUD | 88.081% |
| Race Oncology Limited | 20.22 Million AUD | 46.239% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | 84.903% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | -70.734% |
| Starpharma Holdings Limited | 36.81 Million AUD | 70.459% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 97.27% |
| Tissue Repair Ltd | 19.38 Million AUD | 43.913% |
| Zelira Therapeutics Limited | 5.18 Million AUD | -109.806% |